COMPANY RESEARCHSanofi is a France-based global biopharmaceutical company active in researching, developing and commercializing innovative medicines and vaccines. Its broad scientific capabilities cover immunology, rare diseases and other therapeutic areas, supported by internal platforms and external research collaborations. The official share-information page confirms ordinary shares on Euronext Paris under SAN and Nasdaq-listed American depositary shares under SNY; these are instruments of the same issuer. Its scientific organization encompasses biologics, vaccines and therapies for immune-related conditions.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Sanofi is a France-based global biopharmaceutical company active in researching, developing and commercializing innovative medicines and vaccines. Its broad scientific capabilities cover immunology, rare diseases and other therapeutic areas, supported by internal platforms and external research collaborations. The official share-information page confirms ordinary shares on Euronext Paris under SAN and Nasdaq-listed American depositary shares under SNY; these are instruments of the same issuer. Its scientific organization encompasses biologics, vaccines and therapies for immune-related conditions.
Euronext Paris: SAN Nasdaq: SNY
biologics · small-molecule · vaccines
immunology · rare-diseases · vaccines
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Kymera's Q2 2026 update reports that Sanofi began first-in-human Phase 1 KT-485 (SAR447971), an oral IRAK4 degrader, in June. Sanofi is responsible for subsequent development, regulatory work, and commercialization.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| SAR447971 / KT-485 | IRAK4 · See individual trial / indication; not individually confirmed in this review | Phase 1 | Clinical entry; complete human results not confirmed by this source |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 1 / 1 related items
Nurix said Sanofi will stop the first-in-human Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix no longer expects future milestone payments or royalties from this asset, while other licensed programs remain eligible for such payments. The November 3 announcement did not disclose the reason for discontinuation.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.